{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:21:42Z","timestamp":1791350502625,"version":"4.3.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1,2]]},"DOI":"10.1097\/qad.0b013e3283324283","type":"journal-article","created":{"date-parts":[[2009,11,28]],"date-time":"2009-11-28T03:17:41Z","timestamp":1259378261000},"page":"123-137","source":"Crossref","is-referenced-by-count":378,"title":["The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals"],"prefix":"10.1097","volume":"24","member":"276","reference":[{"key":"R1-17-20210130","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N Engl J Med"},{"key":"R2-17-20210130","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team","volume":"337","author":"Hammer","year":"1997","journal-title":"N Engl J Med"},{"key":"R3-17-20210130","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/aje\/kwg206","article-title":"Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models","volume":"158","author":"Cole","year":"2003","journal-title":"Am J Epidemiol"},{"key":"R4-17-20210130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies","volume":"360","author":"Egger","year":"2002","journal-title":"Lancet"},{"key":"R5-17-20210130","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0140-6736(97)04161-5","article-title":"Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group","volume":"351","author":"Cameron","year":"1998","journal-title":"Lancet"},{"key":"R6-17-20210130","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0140-6736(98)22008-3","article-title":"Surrogacy in HIV-1 clinical trials","volume":"351","author":"Pozniak","year":"1998","journal-title":"Lancet"},{"key":"R7-17-20210130","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/0003-4819-118-9-199305010-00003","article-title":"CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine","volume":"118","author":"Choi","year":"1993","journal-title":"Ann Intern Med"},{"key":"R8-17-20210130","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/sim.4780120904","article-title":"Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials","volume":"12","author":"Lin","year":"1993","journal-title":"Stat Med"},{"key":"R10-17-20210130","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/00002030-199814000-00014","article-title":"CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group","volume":"12","author":"Hughes","year":"1998","journal-title":"AIDS"},{"key":"R11-17-20210130","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1051\/medsci\/20082410804","article-title":"Mortality rate of HIV-infected adults compared with the general population: long-term and CD4-lymphocyte-dependent results","volume":"24","author":"Lewden","year":"2008","journal-title":"Med Sci (Paris)"},{"key":"R12-17-20210130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(06)69152-6","article-title":"HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis","volume":"368","author":"May","year":"2006","journal-title":"Lancet"},{"key":"R13-17-20210130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/QAD.0b013e3282f3915e","article-title":"Survival following HIV infection of a cohort followed up from seroconversion in the UK","volume":"22","author":"Ewings","year":"2008","journal-title":"AIDS"},{"key":"R14-17-20210130","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/QAD.0b013e32802ef30c","article-title":"Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy","volume":"21","author":"Lima","year":"2007","journal-title":"AIDS"},{"key":"R15-17-20210130","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/01.aids.0000202651.41397.db","article-title":"Survival and progression to AIDS in a seroconverter cohort in the posthighly active antiretroviral therapy era: effectiveness goes on","volume":"20","author":"Perez-Hoyos","year":"2006","journal-title":"AIDS"},{"key":"R16-17-20210130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.7326\/0003-4819-146-2-200701160-00003","article-title":"Survival of persons with and without HIV infection in Denmark, 1995\u20132005","volume":"146","author":"Lohse","year":"2007","journal-title":"Ann Intern Med"},{"key":"R17-17-20210130","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(03)14570-9","article-title":"Determinants of survival following HIV-1 seroconversion after the introduction of HAART","volume":"362","author":"Porter","year":"2003","journal-title":"Lancet"},{"key":"R19-17-20210130","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hern\u00e1n","year":"2000","journal-title":"Epidemiology"},{"key":"R20-17-20210130","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0140-6736(05)67022-5","article-title":"Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study","volume":"366","author":"Sterne","year":"2005","journal-title":"Lancet"},{"key":"R21-17-20210130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1468-1293.2004.00197.x","article-title":"The UK Collaborative HIV Cohort (UK CHIC) Study.","volume":"5","year":"2004","journal-title":"HIV Med"},{"key":"R22-17-20210130","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1097\/00002030-200310170-00011","article-title":"Mortality and progression to AIDS after starting highly active antiretroviral therapy","volume":"17","author":"van Sighem","year":"2003","journal-title":"AIDS"},{"key":"R23-17-20210130","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/QAD.0b013e3283023f78","article-title":"Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy","volume":"22","author":"Piketty","year":"2008","journal-title":"AIDS"},{"key":"R24-17-20210130","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0140-6736(99)01122-8","article-title":"Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study","volume":"353","author":"Ledergerber","year":"1999","journal-title":"Lancet"},{"key":"R25-17-20210130","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/QAI.0b013e31815ee282","article-title":"Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain)","volume":"47","author":"Jaen","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R26-17-20210130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1157\/13096749","article-title":"Spanish cohort of naive HIV-infected patients (CoRIS): rationale, organization and initial results","volume":"25","author":"Caro-Murillo","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"R27-17-20210130","first-page":"1393","article-title":"Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status","volume":"12","author":"Moreno","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8 Suppl 2","key":"R28-17-20210130","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/01.mlr.0000223741.02074.66","article-title":"Veterans Aging Cohort Study (VACS): overview and description","volume":"44","author":"Justice","year":"2006","journal-title":"Med Care"},{"key":"R30-17-20210130","doi-asserted-by":"crossref","first-page":"e3907","DOI":"10.1371\/journal.pone.0003907","article-title":"Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study","volume":"3","author":"Dalmasso","year":"2008","journal-title":"PLoS ONE"},{"key":"R31-17-20210130","first-page":"2361","article-title":"Does transient HAART during primary HIV-1 infection lower the virological set-point?","volume":"18","author":"Desquilbet","year":"2004","journal-title":"AIDS"},{"key":"R32-17-20210130","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00002030-200302140-00009","article-title":"Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category","volume":"17","author":"Perez-Hoyos","year":"2003","journal-title":"AIDS"},{"key":"R34-17-20210130","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/sim.4780091214","article-title":"Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study","volume":"9","author":"D'Agostino","year":"1990","journal-title":"Stat Med"},{"key":"R35-17-20210130","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/01.ede.0000135174.63482.43","article-title":"A structural approach to selection bias","volume":"15","author":"Hern\u00e1n","year":"2004","journal-title":"Epidemiology"},{"key":"R37-17-20210130","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/0003-4819-145-6-200609190-00003","article-title":"Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City","volume":"145","author":"Sackoff","year":"2006","journal-title":"Ann Intern Med"},{"key":"R38-17-20210130","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1086\/432895","article-title":"Mortality among urban drug users and the impact of highly active antiretroviral therapy","volume":"41","author":"Celentano","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R39-17-20210130","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1371\/journal.pmed.0050203","article-title":"Inflammatory and coagulation biomarkers and mortality in patients with HIV infection","volume":"5","author":"Kuller","year":"2008","journal-title":"PLoS Med"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAD.0b013e3283324283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:07:01Z","timestamp":1786039621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-201001020-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,2]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e3283324283","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1,2]]}}}